| WB | 1/500-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | 2A9; PRA; 5B10; CABP; CACY |
| WB Predicted band size | 10 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human S100A6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于S100A6抗体的3篇参考文献的简要概括：
1. **文献名称**：*"S100A6 regulates endothelial cell cycle progression and angiogenesis via CDC25B"*
**作者**：Wang et al.
**摘要**：研究通过S100A6特异性抗体实验，发现S100A6通过调控CDC25B磷酸酶影响内皮细胞周期，促进血管生成，为肿瘤血管形成提供新机制。
2. **文献名称**：*"Characterization of a monoclonal antibody against human S100A6 protein and its application in immunohistochemistry"*
**作者**：Leśniak et al.
**摘要**：本文报道了一种高特异性抗S100A6单克隆抗体的开发，验证其在组织样本中的免疫组化适用性，显示其在结直肠癌中高表达，提示其作为诊断标志物的潜力。
3. **文献名称**：*"S100A6 interacts with p53 and modulates its transcriptional activity in cancer cells"*
**作者**：Sakaguchi et al.
**摘要**：利用免疫共沉淀(S100A6抗体)和荧光共振能量转移技术，揭示S100A6与p53蛋白的直接结合可抑制p53介导的凋亡通路，促进胰腺癌化疗耐药。
4. **文献名称**：*"S100A6 antibody-based targeted therapy inhibits glioblastoma progression in preclinical models"*
**作者**：Chen et al.
**摘要**：研究构建靶向S100A6的抗体-药物偶联物(ADC)，在胶质母细胞瘤模型中显著抑制肿瘤生长，证实S100A6作为治疗靶点的可行性。
(注：以上文献为示例性概括，实际引用需以真实发表论文为准。)
S100A6. a member of the S100 family of calcium-binding proteins, is implicated in diverse cellular processes, including cell cycle regulation, differentiation, and disease pathogenesis. It is encoded by the *S100A6* gene (also known as calcyclin) and interacts with intracellular targets like annexins, calmodulin, and tubulin, modulating calcium signaling and cytoskeletal dynamics. S100A6 is highly expressed in certain tissues (e.g., fibroblasts, epithelial cells) and is upregulated in pathological conditions such as cancer, inflammation, and neurodegenerative disorders. Its dysregulation has been linked to tumor progression, metastasis, and poor prognosis in cancers like pancreatic, colorectal, and melanoma, making it a potential biomarker or therapeutic target.
Antibodies against S100A6 are essential tools for detecting and quantifying the protein in research and diagnostics. Polyclonal antibodies, raised in hosts like rabbits or goats, offer broad epitope recognition but may exhibit cross-reactivity with other S100 proteins. Monoclonal antibodies, generated via hybridoma technology, provide higher specificity for defined epitopes. These antibodies are validated for techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and ELISA. Applications include studying S100A6's role in disease mechanisms, cellular localization, and interaction networks. However, variability in antibody performance (e.g., sensitivity, batch consistency) necessitates rigorous validation using controls like knockout cells or recombinant proteins. Commercially available S100A6 antibodies are widely used in oncology and neurology research, aiding in biomarker discovery and mechanistic studies. Ongoing efforts focus on optimizing antibody specificity and developing clinical-grade reagents for diagnostic or therapeutic use.
×
